Navigation Links
CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenue Increase
Date:10/9/2008

54) (1,162) (1,582) (4,011)

Other expense, net (175) (232) (533) (680)

Loss before income taxes and minority

interest (429) (1,394) (2,115) (4,691)

Minority interest in income of

subsidiary - (11) (145) (45)

Income tax benefit (provision) (3) 56 (519) (195)

Loss from continuing operations (432) (1,349) (2,779) (4,931)

Income (loss) from discontinued

operations - 496 127 (10,614)

Net loss $(432) $(853) $(2,652) $(15,545)

Net loss per common share:

Basic and diluted $(0.06) $(0.12) $(0.37) $(2.22)

Weighted-average shares used in per

share calculation:

Basic and diluted 7,213 7,031 7,171 7,004

Selected Consolidated Balance Sheet Data

August 31, November 30,

2008 2007

Cash and cash equivalents $6,328 $8,362

Accounts receivable, net 3,861 4,475

Inventory, net 1,195 1,670

Total current assets 11,942 15,164

Long-term assets 4,451 4,703

Total assets 16,393 19,867

Total current liabilities 7,885 5,620

Long-term liabilities 879 4,318

Total liabilities 8,764 9,938

Minority interest 478 407

Shareholders'
'/>"/>

SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcares Centricity(R) Electronic Medical Record (EMR) System
2. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
3. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
4. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
5. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
6. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. Corgenix Reports Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... , INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, ... it has priced a $300 million securitization transaction intended ... royalties. , Upon closing of the transaction, which is ... will sell to QHP Royalty Sub LLC ("QHP"), a ...
... , MINNEAPOLIS, Oct. 28 Techne Corporation,s (Nasdaq: ... September 30, 2009 decreased 6.4% to $26.8 million or ... $.74 per diluted share for the quarter ended September ... mainly due to foreign currency fluctuations, decreased consolidated net ...
... ... of work in September, health care industry continued growing, adding 19,000 new jobs. But ... ... healthcare and related fields continued to grow, even as more Americans found themselves out of ...
Cached Biology Technology:PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 2Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 3Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 4Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 5Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 6The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 2The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 3The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 4
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... MA -- Using ultrasound waves, MIT engineers have found ... drugs, making transdermal drug delivery more efficient. This technology ... needle-free vaccinations, according to the researchers. "This could ... cortisol, for example systemic drugs and proteins such ...
... strides in identifying genes that lead to an increased ... a continuum of social deficits, communication difficulties and cognitive ... these genetic risk factors impact the brain,s structure and ... developed. This led researchers at UCLA ...
... FARMINGTON, Conn., Sept. 13, 2012 /PRNewswire-iReach/ -- Global ... time offer on personalized medicine, next generation sequencing ... Pacific, a bio/pharmaceutical and life sciences industry analyst ... http://photos.prnewswire.com/prnh/20120913/CG74123 ) Personalized Medicine: Companies, Trends ...
Cached Biology News:Getting (drugs) under your skin 2Getting (drugs) under your skin 3Study reveals how common gene mutation affects kids with autism spectrum disorders 2Study reveals how common gene mutation affects kids with autism spectrum disorders 3How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment 2How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment 3
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Biology Products: